The global non invasive prenatal testing market size is anticipated to reach USD 6.5 billion by 2028 registering a CAGR of 10.9%, according to a new report by Grand View Research, Inc. High adoption and demand for early non-invasive prenatal testing (NIPT) coupled with improvements in reimbursement scenario are among the factors driving the market.
The use of invasive techniques of prenatal testing, such as chorionic villus sampling and amniocentesis, can lead to issues, such as miscarriage. This has led to a decline in the use of these procedures and high demand for tests that are more efficient, non-invasive, and safe. Furthermore, non-invasive fetal tests have a lower failure and false-positive rate, which has resulted in a considerable increase in uptake of non-invasive tests in the last few years.
The non-invasive prenatal testing market is highly saturated with the existing key players. Companies are forming partnerships and collaborations to maintain a stable position in the market. For instance, in August 2020, Eurofins Scientific announced an agreement with Noritsu Koki Co., Ltd. for the acquisition of GeneTech Inc., one of the pioneering NIPT developers in Japan. With this acquisition, Eurofins Scientific is set to strengthen its presence in the Japanese NIPT market.
Browse full report with Table of Content @ https://www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market
Non-invasive Prenatal Testing Market Report Highlights
- The 13-24 weeks gestation period segment accounted for the largest revenue share in 2020 owing to the presence of a maximum number of tests carried out in this phase of pregnancy
- NIPT for high- & average-risk pregnancy led the market owing to the presence of favorable payer reimbursement policies in this segment
- Next-Generation Sequencing (NGS) is estimated to be the largest as well as the fastest-growing technology segment from 2021 to 2028, as NGS is the most commonly used method for NIPT
- The diagnostic laboratories end-use segment held the largest revenue share in 2020 and will expand further at the fastest CAGR from 2021 to 2028 due to the rising number of diagnostic laboratories across the globe that offer NIPT
- Asia Pacific is expected to register the fastest year-on-year growth owing to the gradually increasing average maternal age and rising incidence of chromosomal aneuploidies
- One of the key trends followed by market participants includes licensing of the test to other labs and generating significant revenue by collecting royalty payments
For Requesting a Sample Copy of This Report, Please Visit @ https://www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market/request/rs1
Non-invasive Prenatal Testing Market Segmentation
Grand View Research has segmented the global non-invasive prenatal testing market on the basis of the gestation period, risk type, method, technology, product, end-use, and region:
NIPT Gestation Period Outlook (Revenue, USD Million, 2017 – 2028)
- 0-12 Weeks
- 13-24 Weeks
- 25-36 Weeks
NIPT Risk Type Outlook (Revenue, USD Million, 2017 – 2028)
- High & Average Risk
- Low Risk
NIPT Method Outlook (Revenue, USD Million, 2017 – 2028)
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
NIPT Technology Outlook (Revenue, USD Million, 2017 – 2028)
- NGS
- Array Technology
- PCR
- Other Technologies
NIPT Product Outlook (Revenue, USD Million, 2017 – 2028)
- Consumables & Reagents
- Instruments
NIPT End-use Outlook (Revenue, USD Million, 2017 – 2028)
- Hospitals & Clinics
- Diagnostic Laboratories
NIPT Regional Outlook (Revenue, USD Million, 2017 – 2028)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Singapore
- Australia
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
- Saudi Arabia
List of Key Players of Non-invasive Prenatal Testing Market
- Genesis Genetics (CooperSurgical, Inc.)
- Natera, Inc.
- Centogene N.V.
- Illumina, Inc. (Verinata Health, Inc.)
- Eurofins LifeCodexx GmbH
- MedGenome Labs Ltd.
- F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
- Myriad Women’s Health, Inc. (Myriad Genetics Inc/Counsyl, Inc.)
- Progenity, Inc.
- Qiagen
- Laboratory Corp. of America Holdings
- Quest Diagnostics, Inc.
Inquire more or share questions if any before the purchase on this report @ https://www.grandviewresearch.com/inquiry/1840/ibb
Browse More Related Report:
Medical Image Analysis Software Market Size, Share & Trends Analysis Report By Software Type, By Modality (Radiographic, Ultrasound), By Imaging Type, By End Use, By Application, And Segment Forecasts, 2020 – 2027
About Grand View Research
Grand View Research is a full-time market research and consulting company registered in San Francisco, California. The company fully offers market reports, both customized and syndicates, based on intense data analysis. It also offers consulting services to business communities and academic institutions and helps them understand the global and business scenario to a significant extent. The company operates across multitude of domains such as Chemicals, Materials, Food and Beverages, Consumer Goods, Healthcare, and Information Technology to offer consulting services.
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market